StockData
Regencell Bioscience Holdings Ltd logo

Regencell Bioscience Holdings Ltd (RGC) income statement

RGCNasdaqMedicinal Chemicals & Botanical Products
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Oct 7, 2026Score 5/30
$4.36−0.33 (-7.04%)

Close on Nov 19, 2026Market cap $2.16BP/E –Yield –

Regencell Bioscience Holdings Ltd income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2026
-128.5%

Financial strength

Current ratio
10.77
Debt to equity
–
Debt to assets
–
Cash to current liabilities
1074.6%

Valuation

P/E ratio
–
Price to sales
–
Price to book
161.96
Dividend yield
–

See a number that looks wrong?